ArticlePediatric research2026
Impact of mercaptopurine schedule on hypoglycemia in leukemic children: randomized trial and risk factor analysis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The utility of pyrimidine derivatives in the construction of azolo[RSC advances · 2026Review
- Continuous Glucose Monitoring for Detecting Hypoglycemia During Maintenance Therapy for Acute Lymphoblastic Leukemia.Pediatrics international : official journal of the Japan Pediatric SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChildren with acute lymphoblastic leukemia (ALL) may develop hypoglycemia, potentially attributable to mercaptopurine (6-MP) during long-term maintenance chemotherapy. Since hypoglycemia is harmful to childhood neurodevelopment, it is necessary to examine its occurrence during chemotherapy with and without 6-MP beyond the maintenance stage for ALL, along with the risk factors.
methodsALL patients received CAM-1 regimen (cyclophosphamide, cytarabine, and 6-MP). 6-MP was randomized to conventional administration at night before bedtime (Group A) or in the afternoon between lunch and dinner (Group B). Children with acute myeloid leukemia received non-6MP-containing chemotherapy (Group C).
resultsGroup C showed no hypoglycemia. Among patients on CAM-1, 33% developed hypoglycemia, 48% of whom were symptomatic. There was no significant difference in hypoglycemic incidence (P = 0.933) between Groups A and B. No further hypoglycemic episodes were observed after shortening overnight fasting period in most cases. Multivariate analysis identified young age, higher serum bilirubin levels, and longer overnight fasting as significant risk factors for hypoglycemia in children receiving 6-MP.
conclusionHypoglycemia is also prevalent in children exposed to short-term 6-MP but not in those without such exposure. Shortening overnight fasting period, rather than changing 6-MP schedule, is more critical in preventing hypoglycemia in young children. IMPACT: This study reveals that hypoglycemia occurs frequently in children with short-term exposure to 6-MP, as documented for long-term exposure in published literature. The data demonstrate that it is 6-MP that is directly associated with hypoglycemia. Prolonged durations of overnight fasting, especially in younger individuals with hepatotoxicity, constitute a risk factor for developing hypoglycemia. Shortening the overnight fasting period, rather than changing the 6-MP schedule, is critical to prevent hypoglycemia and adverse neurodevelopment in children, even if they are receiving short-term 6-MP treatment.
Identifiers
41484357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.